UniQure said on Monday the U.S. drug regulator had informed that data from an early- to mid-stage trial of its brain disorder ...

The cell therapy manufacturing market offers significant opportunities driven by technological advancements, increasing clinical trials, and growing regulatory approvals. Key growth catalysts include ...

Thanks to advances in imaging and diagnostic technologies, clinicians can now detect many genetic disorders in the womb, ...

Qure stock plunged 45% after FDA rejected AMT-130 approval pathway, requiring new randomized trial for Huntington's disease gene therapy program.

uniQure held a Type A meeting with the FDA at the end of January and, in a statement released today, said the agency "cannot agree that data from the Phase I/II studies, compared to an external ...

Qure NV (QURE) reports promising data on Huntington's disease treatment while navigating regulatory hurdles and financial setbacks.

Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of ...

Please refer to the earnings press release issued this morning and our quarterly filing with the SEC for additional details. Revenue for the year ended 12/31/2025 was $16.1 million compared to $27.1 ...

Genetix delivers strong 2025 revenue growth resulting in the Company’s first ever profitable quarterIn 2025, >100 U.S. patients were treated and >150 U.S. patients completed their first cell ...

Obviously caveats must be drawn from a mouse model such as this, but the results have supercharged the team's determination.

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsChristopher Viehbacher - President, CEO ...

AMT-130 is a gene therapy designed to lower levels of the huntingtin protein in the brain. It uses a harmless virus package, called an adeno-associated virus (AAV), to contain microRNA – genetic ...